A.R.T. Advisors’s Zevra Therapeutics ZVRA Stock Holding History

A.R.T. Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-950	Closed	-$25K	–	1673
2019 Q1	$25K	Buy	+950	New	+$34.9K	﹤0.01%	1248
2016 Q2	–	Sell	-854	Closed	-$198K	–	1683
2016 Q1	$198K	Buy	+854	New	+$207K	0.01%	1171
2015 Q4	–	Sell	-1,304	Closed	-$404K	–	1755
2015 Q3	$404K	Buy	+1,304	New	+$399K	0.02%	949

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

A.R.T. Advisors's ZVRA Position: Q2 2019 in Review

A.R.T. Advisors sold out of Zevra Therapeutics (ZVRA) in Q2 2019, closing a stake of 950 shares — an estimated $25K sold.

A.R.T. Advisors first reported a position in ZVRA in Q3 2015 and held it in 3 quarters. The position peaked at $404K in Q3 2015. 32 funds tracked by Wall St. Rank hold ZVRA as of Q2 2019.

A.R.T. Advisors reported no remaining Zevra Therapeutics position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 950 Zevra Therapeutics shares in Q2 2019, an estimated $25K.
A.R.T. Advisors first reported a position in Zevra Therapeutics in Q3 2015 and held it in 3 quarters.
A.R.T. Advisors's Zevra Therapeutics position peaked at $404K in Q3 2015.
32 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.